Rigel Pharmaceuticals (RIGL) Current Deferred Revenue (2011 - 2025)

Rigel Pharmaceuticals has reported Current Deferred Revenue for 15 years, with the latest figure at $1.4 million in Q3 2025.

• For the quarter ending Q3 2025, Current Deferred Revenue changed 0.0% year-over-year to $1.4 million; the trailing twelve-month figure through Sep 2025 stood at $1.4 million (changed 0.0% YoY), and the FY2024 full-year result was $1.4 million, changed 0.0% from the prior year.
• Current Deferred Revenue for Q3 2025 stood at $1.4 million, roughly flat from $1.4 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $9.5 million in Q1 2021, with the low at $1.4 million in Q2 2023.
• Average Current Deferred Revenue over 5 years is $2.2 million, with a median of $1.4 million recorded in 2023.
• Year-over-year, Current Deferred Revenue jumped 362.74% in 2021 and sank 77.93% in 2022.
• Tracing RIGL's Current Deferred Revenue over 5 years: stood at $2.6 million in 2021, then plunged by 47.27% to $1.4 million in 2022, then slipped by 1.02% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
• The last three Current Deferred Revenue figures came in at $1.4 million (Q3 2025), $1.4 million (Q2 2025), and $1.4 million (Q1 2025), per Business Quant data.

Peer Comparison